A flow cytometry and immunophenotyping add-on that quantifies antigen density and measures drug response within defined malignant populations — resolving efficacy and selectivity that bulk-well readouts average away.
Bulk viability measures average cell response in the well, which can obscure a compound’s true effects. Multiparameter flow distinguishes drug impact within malignant cells and immune populations, allowing separation of efficacy from off-target killing.
Target marker expression on malignant vs. non-malignant cells, with quantitative antigen-density analysis where validated — directly relevant to ADC, bispecific, T-cell-engager, and degrader programs.
Drug sensitivity is measured within specific immunophenotypes, including CD34+ leukemic stem cells, lymphoma subsets, and plasma-cell compartments.
Apply fit-for-purpose marker panels and gating strategies to resolve population identity, viability, and treatment-induced phenotypic change.
Layers onto any live-cell service to add population-level resolution, commonly paired with Combination Optimization and Immunotherapy Translational.
Key Deliverables
A scientist — not a sales desk — will scope a tailored study and return a design and timeline.
